Filing Flows › Usana Health Sciences (USNA) › Q1 2026 › vs Q4 2025
Usana Health Sciences (USNA) Q1 2026 vs Q4 2025 (quarter over quarter)
Usana Health Sciences's revenue rose $24.0M (+11%) from $226M in Q4 2025 to $250M in Q1 2026. Gross margin 76.2% against 78.2% (-1.9 pts).
Usana Health Sciences, Q1 2026: revenue $250M (+0.3% year over year), operating margin 5.5%, net earnings $7.5M, operating cash flow $9.8M. The chart draws each line against Q4 2025, the increases inside each band.
Margins
| Q1 2026 | Q4 2025 | Change | |
|---|---|---|---|
| Gross margin | 76.2% | 78.2% | -1.9 pts |
| Operating margin | 5.5% | 1.7% | +3.9 pts |
| Net margin | 3.0% | -0.8% | +3.8 pts |
| Free cash flow margin | 2.8% | -2.7% | +5.6 pts |
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $250M | $226M | $24.0M | +11% |
| Gross profit | $191M | $177M | $14.0M | +8% |
| Cost of revenue | $59.4M | $49.4M | $10.0M | +20% |
| Other income, net | $1.6M | $358K | $1.2M | +344% |
| Operating profit | $13.9M | $3.8M | $10.1M | +263% |
| Operating expenses | $177M | $173M | $3.9M | +2% |
| Pre-tax earnings | $15.5M | $4.2M | $11.3M | +270% |
| SG&A | $88.3M | $78.1M | $10.2M | +13% |
| Other operating costs | $88.7M | $94.9M | −$6.2M | -7% |
| Loss borne by minority interests | $556K | −$180K | $736K | — |
| Net earnings | $7.5M | −$1.8M | $9.3M | — |
| Income tax | $8.5M | $5.8M | $2.7M | +47% |
| Operating cash sources | $19.2M | $10.5M | $8.7M | +83% |
| Depreciation & amortization | $8.3M | $8.6M | −$284K | -3% |
| Share-based compensation | $3.5M | $3.8M | −$296K | -8% |
| Working capital & other | $9.5M | $13.9M | −$4.4M | -32% |
| Operating cash flow | $9.8M | −$3.4M | $13.1M | — |
| Free cash flow (OCF − capex) | $7.1M | −$6.2M | $13.3M | — |
| Capital expenditures | $2.6M | $2.8M | −$150K | -5% |
Questions
How much did Usana Health Sciences's revenue grow quarter over quarter in Q1 2026?
Usana Health Sciences's revenue rose $24.0M (+11%) from $226M in Q4 2025 to $250M in Q1 2026. Gross margin 76.2% against 78.2% (-1.9 pts).